Combining nicotine patches and mouth spray to help quit vaping
The New Zealand Quit Vaping Trial: Combination Nicotine Replacement Therapy Versus Nicotine Reduction.
This study is testing if using both nicotine patches and mouth spray can help people who vape quit more successfully than just reducing their nicotine gradually.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 774 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | University of Auckland, New Zealand Academic / other |
| Locations | 1 site (Auckland) |
| Trial ID | NCT06832098 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a combination of nicotine patches and mouth spray compared to a nicotine tapering plan for vaping cessation. Conducted in New Zealand, it aims to determine which method, along with behavioral support, leads to higher rates of vaping abstinence after six months. Participants will be randomly assigned to one of the two treatment groups and will receive written support to aid their quitting efforts. The study targets individuals who vape regularly and are motivated to quit within the next eight weeks.
Who should consider this trial
Good fit: Ideal candidates are New Zealand residents aged 16 and older who vape nicotine weekly and are motivated to quit within the next two months.
Not a fit: Patients who currently smoke tobacco or have recently been regular tobacco users may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the chances of long-term vaping cessation for participants.
How similar studies have performed: Previous studies on nicotine replacement therapies have shown promise, but this specific combination approach is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Live in New Zealand. * Vape nicotine at least weekly (one or more days out of the past seven days). * Used to smoke (i.e. they have smoked tobacco regularly but not at all in the past six months) or have never smoked (i.e., they have never been a regular user of smoked tobacco, defined as less than 100 cigarettes in their lifetime). * Are aged ≥16 years. * Are motivated to quit vaping in the next eight weeks. * Are able to provide consent. * Have access to the internet via a computer or smart phone. * Are a registered patient at a New Zealand medical facility. Exclusion Criteria: * They have another person in their household currently enrolled in the study. * They smoke tobacco currently or were a recent regular user of tobacco. * They are enrolled in another vaping cessation programme/trial. * They self-report having had a serious cardiovascular event, or hospitalisation for a cardiovascular complaint, in the previous four weeks (e.g. stroke, myocardial infarction, unstable angina, cardiac arrhythmia, coronary artery bypass graft and angioplasty). * They self-report uncontrolled hypertension. * They have a strong preference to use/not use NRT or nicotine tapering. * They are current users of smoking cessation pharmacotherapy (e.g. NRT, varenicline, cytisine, nortriptyline \[including if it is used for a different indication\], and amitriptyline \[as it converts to nortriptyline\]. * They are currently enrolled in another vaping cessation programme/trial.
Where this trial is running
Auckland
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland — Auckland, New Zealand (Recruiting)
Study contacts
- Principal investigator: George Laking, PhD, MBChB — University of Auckland, New Zealand
- Study coordinator: Amanda Calder, PhD
- Email: amanda.calder@auckland.ac.nz
- Phone: +64 9 373 7599
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.